Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Matt Phipps

AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day

AbbVie stock broke out Thursday after the pharma announced it had entered a deal that will stave off generic Rinvoq until April 2037.

Investors Business Daily

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Benzinga

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Investors Business Daily

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

Investors Business Daily

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Bristol Myers Screams To A Year-High After Walloping Profit Expectations

Bristol Myers Squibb walloped profit expectations in the September quarter, and Bristol Myers stock screamed to a year-high.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Investors Business Daily

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations

NewAmsterdam said Monday its experimental drug lowered "bad" LDL cholesterol But the results were below biotech stock analysts' views.

Investors Business Daily

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Merus stock catapulted to a record high Friday after its experimental regimen for head-and-neck cancer beat expectations in a key study.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.